Guardant Health, Pfizer Begin Partnership to Test Prospective Cancer Therapies in China

MT Newswires Live

Apr 24, 2025

Guardant Health (GH) and Pfizer, (PFE) disclosed a new, multi-year collaboration agreement on Thursday to support development and commercialization of Pfizer's oncology portfolio using the Guardant's Infinity liquid biopsy platform.

Under the terms of the new partnership, the companies will evaluate the clinical use of circulating tumor DNA levels as a surrogate endpoint to monitor therapy response as well as related blood-based epigenomic analysis.

The collaboration also will provide Pfizer with access to Guardant's liquid biopsy tests in China as the companies conduct clinical trials that include Chinese cohorts. Guardant previously formed a strategic partnership with Hong Kong-listed Adicon Holdings to offer Guardant tests to biopharmaceutical companies conducting clinical studies in China.

Guardant shares recently were more than 1% higher in Thursday trading. Pfizer was narrowly higher this morning.

Price: 46.30, Change: +0.66, Percent Change: +1.45

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2529222931"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2529222931\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2529222931?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-24 22:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2529222931","market":"fut","top_or_hot":-1,"title":"Guardant Health, Pfizer Begin Partnership to Test Prospective Cancer Therapies in China","media":"MT Newswires Live","content":"<html><body><p> Guardant Health (GH) and Pfizer, (PFE) disclosed a new, multi-year collaboration agreement on Thursday to support development and commercialization of Pfizer's oncology portfolio using the Guardant's Infinity liquid biopsy platform.</p><p>Under the terms of the new partnership, the companies will evaluate the clinical use of circulating tumor DNA levels as a surrogate endpoint to monitor therapy response as well as related blood-based epigenomic analysis.</p><p>The collaboration also will provide Pfizer with access to Guardant's liquid biopsy tests in China as the companies conduct clinical trials that include Chinese cohorts. Guardant previously formed a strategic partnership with Hong Kong-listed Adicon Holdings to offer Guardant tests to biopharmaceutical companies conducting clinical studies in China.</p><p>Guardant shares recently were more than 1% higher in Thursday trading. Pfizer was narrowly higher this morning.</p><p>Price: 46.30, Change: +0.66, Percent Change: +1.45</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Guardant Health, Pfizer Begin Partnership to Test Prospective Cancer Therapies in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGuardant Health, Pfizer Begin Partnership to Test Prospective Cancer Therapies in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-24 22:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Guardant Health (GH) and Pfizer, (PFE) disclosed a new, multi-year collaboration agreement on Thursday to support development and commercialization of Pfizer's oncology portfolio using the Guardant's Infinity liquid biopsy platform.</p><p>Under the terms of the new partnership, the companies will evaluate the clinical use of circulating tumor DNA levels as a surrogate endpoint to monitor therapy response as well as related blood-based epigenomic analysis.</p><p>The collaboration also will provide Pfizer with access to Guardant's liquid biopsy tests in China as the companies conduct clinical trials that include Chinese cohorts. Guardant previously formed a strategic partnership with Hong Kong-listed Adicon Holdings to offer Guardant tests to biopharmaceutical companies conducting clinical studies in China.</p><p>Guardant shares recently were more than 1% higher in Thursday trading. Pfizer was narrowly higher this morning.</p><p>Price: 46.30, Change: +0.66, Percent Change: +1.45</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4599","symbol_name":"减肥药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2529222931","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2529222931","pubTimestamp":1745503584,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Guardant Health  and Pfizer,  disclosed a new, multi-year collaboration agreement on Thursday to support development and commercialization of Pfizer's oncology portfolio using the Guardant's Infinity liquid biopsy platform.Under the terms of the new partnership, the companies will evaluate the clinical use of circulating tumor DNA levels as a surrogate endpoint to monitor therapy response as well as related blood-based epigenomic analysis.The collaboration also will provide Pfizer with access to Guardant's liquid biopsy tests in China as the companies conduct clinical trials that include Chinese cohorts. Guardant previously formed a strategic partnership with Hong Kong-listed Adicon Holdings to offer Guardant tests to biopharmaceutical companies conducting clinical studies in China.Guardant shares recently were more than 1% higher in Thursday trading. Pfizer was narrowly higher this morning.Price: 46.30, Change: +0.66, Percent Change: +1.45","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4599":"减肥药","SG9999002232.USD":"Allianz Global High Payout USD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","PFE":"辉瑞","BK7095":"多种金属与采矿","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","GH":"Guardant Health Inc.","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","BK4535":"淡马锡持仓","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4592":"伊斯兰概念","LU0234572021.USD":"高盛美国核心股票组合Acc","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0122379950.USD":"贝莱德世界健康科学A2","PFE.AU":"PANTERA MINERALS LTD","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0058720904.USD":"联博国际健康护理基金A","BK4588":"碎股","BK4550":"红杉资本持仓","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4568":"美国抗疫概念","SG9999001176.USD":"United Global Healthcare Acc USD","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","BK4007":"制药","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4551":"寇图资本持仓","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4196":"保健护理服务","BK4581":"高盛持仓"},"translate_title":"Guardant Health与辉瑞开始合作在中国测试前瞻性癌症疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE.AU":1,"PFE":1,"GH":0.9},"content_text":"Guardant Health (GH) and Pfizer, (PFE) disclosed a new, multi-year collaboration agreement on Thursday to support development and commercialization of Pfizer's oncology portfolio using the Guardant's Infinity liquid biopsy platform.Under the terms of the new partnership, the companies will evaluate the clinical use of circulating tumor DNA levels as a surrogate endpoint to monitor therapy response as well as related blood-based epigenomic analysis.The collaboration also will provide Pfizer with access to Guardant's liquid biopsy tests in China as the companies conduct clinical trials that include Chinese cohorts. Guardant previously formed a strategic partnership with Hong Kong-listed Adicon Holdings to offer Guardant tests to biopharmaceutical companies conducting clinical studies in China.Guardant shares recently were more than 1% higher in Thursday trading. Pfizer was narrowly higher this morning.Price: 46.30, Change: +0.66, Percent Change: +1.45","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}